Indoco Remedies Q3 Results Review - Another Quarter Of Weak Margins: Prabhudas Lilladher

Prabhudas Lilladher Report

Indoco Remedies Ltd.'s cut our FY25/FY26 earning per share by ~10%/4% to factor in low margins and lower sales across regulated markets. We downgrade stock from 'Buy' to 'Accumulate' given weak earnings visibility, muted domestic formulation sales.

Our numbers do factor in margin recovery with reduction in remediation cost from FY25. Indoco Remedies Q3 FY24 Ebitda was sharply below our estimates led by continued higher remediation cost and lower regulated market sales.

The recent official action indicated to its Goa unit- two is negative and will restrict growth in U.S. sales in FY24/H1 FY25.

We expect 18% profit after tax compound annual growth rate over FY23-26E.

At current market price, stock is trading at 20.5 times FY25E earning per share.

We downgrade stock to 'Accumulate' from 'Buy' with revised target price of Rs 380 valuing at 18 times December 2025E earning per share, as we roll forward. Timely resolution of Goa facility unit-two is a key for re-rating.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.